spinner Costamed

Convidicea (Ad5-nCoV) from CanSino Biologics Inc. COVID-19 vaccines

26/02/2021 Epidemiology

General data.

  • Name: Ad5-nCoV trade named Convidicea.
  • Manufacturer Laboratory: CanSino Biologics Inc. and the Beijing Institute of Biotechnology.
  • Type: Vector * To learn more about the type of vaccines, see our blog “The war has begun. Vaccines against COVID-19 ”.
  • Dosage: Single dose.
  • Ingredients: No precise information yet.
  • Injection site: Intramuscular in the arm.
  • Recommended age: 18 years old and up.
  • Immediate Allergic Reactions:
EXPECTED SYMPTOMS

In the injection arm:

  • Pain
  • Swelling
  • Sensitivity

 

In the body in general:

• Fever up to 38.5 ° C

• General weakness or fatigue

• Pain in Muscles, Joints and Head.

  • Special considerations: Check with your doctor before applying the vaccine if you meet any of the following points:
  1. You have allergies, specify which ones.
  2. Have fever.
  3. You have a blood disorder (such as Hemophilia) or if you are taking anticoagulants.
  4. You have a condition that compromises your immune system (eg Lupus) or you take medications that affect your immune system.
  5. You are pregnant or plan to become pregnant.
  6. You are breastfeeding.
  7. You were inoculated with another COVID-19 vaccine.
  • Safety
  1. This vaccine has been approved for emergency use by the Chinese Government since June 25, 2020, authorizing its application to the Army. Since February 10, 2021, it also had its approval by COFEPRIS in Mexico for emergent use. In addition to being applied in China and Mexico, it has an application authorization in Indonesia.
  2. Interesting Note: For the clinical trials, 30 thousand volunteers were recruited around the world, almost half of them of Mexican origin.

 

  • Effectiveness: 
  1. In phase III clinical trials, it registered an effectiveness of 65.7% for the prevention of COVID-19 cases, laboratory data with people without evidence of previous infections.
  2. Its effectiveness rises to 90.98% when it comes to preventing a serious illness derived from the SARS-CoV2 virus, reducing mortality in the event of acquiring the COVID-19 disease.

 

 

Bibliography

 

 

 

 

Like it? Share it!